Procaps S.A.

Procaps S. A. is a Colombian company that specializes in the development and commercialization of pharmaceutical and nutraceutical products, focusing on health solutions across multiple markets worldwide. Procaps S.

A. was founded in 1977 and is based in Barranquilla, Colombia. The company specializes in the production of pharmaceutical and nutraceutical products, including OTC medications and nutritional supplements. In March 2021, Procaps merged with Union Acquisition Corp.

II, a SPAC, for USD 200 mn, signaling its transition to a publicly listed entity. The firm has successfully completed a total of 3 funding deals, with the most recent being the Trade Sale in March 2021. Ruben Minski serves as the CEO of the company. Procaps Group, S.

A. specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical and nutraceutical products, including over-the-counter (OTC) medications, prescription drugs (Rx), nutritional supplements, and high-potency clinical solutions. The company's core offerings are designed to address various health and wellness needs, catering to both individual consumers seeking OTC solutions and healthcare providers looking for effective prescription medications. Procaps primarily serves a global client base that spans over 50 countries across five continents, with a significant presence in North America, Latin America, and select markets in Europe and Asia.

The company’s products are aimed at improving health outcomes and enhancing quality of life, reflecting its commitment to innovation in the healthcare sector. Procaps Group generated revenue of USD 270. 44 mn in 2023, with an EBITDA of USD 59. 82 mn.

The firm employs a structured transaction model that includes both B2B partnerships and direct-to-consumer sales, collaborating with healthcare providers, pharmacies, and distributors to deliver its pharmaceutical and nutraceutical solutions. Pricing structures are tailored to the specific market segments served, allowing for a steady revenue stream through established relationships with clients in the healthcare and wellness sectors. Procaps S. A.

is focusing on the development of new pharmaceutical and nutraceutical products, although specific upcoming releases have not been disclosed. The company aims to expand its market reach, particularly targeting new regions in North America and Europe by 2024. The recent funding from the merger with Union Acquisition Corp. II, completed in September 2021, will support these growth initiatives by providing the necessary capital for product development and market entry.